Miguel Abboud to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Miguel Abboud has written about Dose-Response Relationship, Drug.
Connection Strength
0.133
-
Isolated Central Nervous System Relapse Following Treatment Reduction in Low-risk Acute Lymphoblastic Leukemia at the Children's Cancer Center of Lebanon. J Pediatr Hematol Oncol. 2020 08; 42(6):e428-e433.
Score: 0.034
-
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019 08 08; 381(6):509-519.
Score: 0.031
-
A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2014 Jul; 89(7):709-13.
Score: 0.022
-
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2013 Nov; 88(11):E255-60.
Score: 0.021
-
Addition of ketamine to propofol for initiation of procedural anesthesia in children reduces propofol consumption and preserves hemodynamic stability. Acta Anaesthesiol Scand. 2008 Apr; 52(4):561-5.
Score: 0.014
-
Safety of purified poloxamer 188 in sickle cell disease: phase I study of a non-ionic surfactant in the management of acute chest syndrome. Hemoglobin. 2004 May; 28(2):85-102.
Score: 0.011